Q-linea AB (SE:QLINEA)
:QLINEA
Top Page
Q-linea AB
(QLINEA)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr21.00
▼(-27.59% Downside)
Action:ReiteratedDate:02/07/26
The score is primarily weighed down by weak financial performance: persistent large losses, negative gross profit, and heavy ongoing cash burn despite the 2025 revenue rebound. Technicals add further pressure due to a negative MACD and a long-term downtrend versus the 200DMA, while valuation is constrained by a negative P/E and no dividend.
Positive Factors
Recurring consumables revenue model
The company's business model generates repeatable revenues from single-use cartridges and reagents tied to each instrument placement. Over a multi-month horizon this creates predictable demand per installed unit, supporting scaleable, annuity-like revenue as the installed base grows.
Negative Factors
Negative gross profit and weak unit economics
Persistent negative gross profit indicates the core testing business currently loses money before overheads. Without meaningful margin improvement at the assay or production level, the company cannot leverage revenue growth into sustainable profitability and will remain reliant on external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue model
The company's business model generates repeatable revenues from single-use cartridges and reagents tied to each instrument placement. Over a multi-month horizon this creates predictable demand per installed unit, supporting scaleable, annuity-like revenue as the installed base grows.
Read all positive factors
Q-linea AB (QLINEA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr409.65M
Dividend YieldN/A
Average Volume (3M)13.43K
Price to Earnings (P/E)―
Beta (1Y)2.76
Revenue Growth270.64%
EPS Growth62.29%
CountrySE
Employees97
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-3.73
Shares Outstanding18,949,081
10 Day Avg. Volume10,725
30 Day Avg. Volume13,430
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.51
Revenue Forecast (FY)kr107.00M
Q-linea AB Business Overview & Revenue Model
Company Description
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, a...
How the Company Makes Money
Q-linea makes money by selling and supporting its diagnostic platform and the recurring consumables required to run tests on it. Its revenue model typically comprises: (1) Instrument/system revenue: one-time sales (or potentially placements under ...
Q-linea AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
47
Neutral
Cash Flow
16
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.10M | 2.36M | 4.44M | 12.79M | 9.34M |
| Gross Profit | -180.02M | -11.11M | 995.00K | -21.38M | -25.03M |
| EBITDA | -160.54M | -195.40M | -210.99M | -252.69M | -218.48M |
| Net Income | -182.49M | -216.87M | -229.37M | -275.77M | -233.18M |
Balance Sheet | |||||
| Total Assets | 369.67M | 147.99M | 231.98M | 207.39M | 466.63M |
| Cash, Cash Equivalents and Short-Term Investments | 258.11M | 25.66M | 81.89M | 72.62M | 166.03M |
| Total Debt | 7.71M | 151.21M | 20.56M | 20.93M | 79.00K |
| Total Liabilities | 31.66M | 175.45M | 42.34M | 45.76M | 35.84M |
| Stockholders Equity | 338.00M | -27.46M | 189.64M | 161.63M | 430.79M |
Cash Flow | |||||
| Free Cash Flow | -169.68M | -187.49M | -236.86M | -268.11M | -267.02M |
| Operating Cash Flow | -162.12M | -182.50M | -228.52M | -250.86M | -255.05M |
| Investing Cash Flow | -7.22M | -5.04M | -7.77M | 315.25M | -23.82M |
| Financing Cash Flow | 402.12M | 131.27M | 245.41M | -6.60M | 283.81M |
Q-linea AB Technical Analysis
Negative
29.00
Price Trends
23.72
Negative
24.52
Negative
32.63
Negative
Market Momentum
-0.16
Negative
41.93
Neutral
45.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLINEA, the sentiment is Negative. The current price of 29 is above the 20-day moving average (MA) of 22.78, above the 50-day MA of 23.72, and below the 200-day MA of 32.63, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 41.93 is Neutral, neither overbought nor oversold. The STOCH value of 45.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:QLINEA.
Q-linea AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr540.57M | -1.69 | -35.70% | ― | -18.46% | 4.90% | |
50 Neutral | kr2.81B | -5.68 | -49.96% | ― | -91.85% | -6.65% | |
49 Neutral | kr193.12M | -2.92 | -51.35% | ― | ― | -34.02% | |
45 Neutral | kr110.90M | -1.81 | -72.82% | ― | 40.91% | 57.92% | |
42 Neutral | kr409.65M | -0.91 | -108.15% | ― | 270.64% | 62.29% | |
42 Neutral | kr24.20M | -0.24 | -186.13% | ― | ― | 0.30% |
* Healthcare Sector Average
SE:QLINEA
Q-linea AB
22.00
-18.62
-45.83%
SE:VICO
Vicore Pharma Holding AB
9.97
3.47
53.38%
SE:ISOFOL
Isofol Medical AB
0.69
-0.87
-55.79%
SE:BIOVIC.B
Biovica International AB Class B
0.38
-0.34
-47.03%
SE:DOXA
Doxa AB
0.42
0.07
19.66%
SE:GUARD
Guard Therapeutics International AB
1.20
-12.20
-91.04%
Q-linea AB Corporate Events
Q-linea Expands Middle East Presence With ASTar Deployments in Saudi Arabia
Apr 2, 2026
Q-linea has expanded its Middle East footprint by shipping two ASTar instruments to hospitals in Saudi Arabia, where local distributor AMICO will oversee installation and evaluations ahead of anticipated clinical use in 2026. These units build on ...
Q-linea Nomination Committee Proposes Stable Board and New Expertise Ahead of 2026 AGM
Mar 11, 2026
Q-linea AB’s nomination committee has proposed a largely unchanged board for the 2026 annual general meeting, with the addition of two new members, investment manager Öystein Engebretsen and Medistim CEO Kari Krogstad, while current dir...
Q-linea Boosts Capital and Global Footprint as ASTar Rollout Accelerates
Feb 4, 2026
Q-linea reported full-year 2025 net sales of SEK 11.1 million, up from SEK 2.4 million a year earlier, while narrowing its operating loss to SEK 176.7 million and strengthening its balance sheet with a nearly fully subscribed rights issue that rai...
Q-linea Wins ASTar Contract with Major U.S. Hospital System
Jan 19, 2026
Q-linea AB has signed a contract for the adoption of its ASTar® rapid antibiotic susceptibility testing system by a large independent health system in the southeastern United States, specializing in cancer and pediatric care, following an eva...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.